Oak Street Health Valuation
Is OSH * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OSH * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OSH * (MX$536.37) is trading below our estimate of fair value (MX$843.2)
Significantly Below Fair Value: OSH * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OSH *?
Other financial metrics that can be useful for relative valuation.
What is OSH *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$9.52b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.8x |
Enterprise Value/EBITDA | -24.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OSH *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2x | ||
CHE Chemed | 3.7x | 6.8% | US$8.5b |
RCM R1 RCM | 2.3x | 11.2% | US$5.2b |
SHL Sonic Healthcare | 1.5x | 5.2% | AU$12.6b |
FME Fresenius Medical Care | 0.6x | 3.6% | €11.5b |
OSH * Oak Street Health | 4.4x | 23.4% | Mex$9.5b |
Price-To-Sales vs Peers: OSH * is expensive based on its Price-To-Sales Ratio (4.4x) compared to the peer average (3.1x).
Price to Earnings Ratio vs Industry
How does OSH *'s PE Ratio compare vs other companies in the South American Healthcare Industry?
Price-To-Sales vs Industry: OSH * is expensive based on its Price-To-Sales Ratio (4.4x) compared to the South American Healthcare industry average (1.1x).
Price to Sales Ratio vs Fair Ratio
What is OSH *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 4.4x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate OSH *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.